Anti-Hyperglycemic Medication Management in the Perioperative Setting: A Review and Illustrative Case of an Adverse Effect of GLP-1 Receptor Agonist

A host of anti-hyperglycemic agents are currently available and widely prescribed for diabetes and weight loss management. In patients undergoing surgery, use of these agents poses a clinical challenge to surgeons, anesthesiologists, and other perioperative care providers with regard to optimal timing of discontinuation and resumption of use, as well as possible effects of these agents on physiology and risk of postoperative complications. Here, we provide a comprehensive review of anti-hyperglycemic medications’ effects on physiology, risks/benefits, and best practice management in the perioperative setting. Additionally, we report an illustrative case of small bowel obstruction in a patient taking semaglutide for 6 months prior to an otherwise uncomplicated laparoscopic hysterectomy and bilateral salpingo-oophorectomy. This review is meant to serve not as a replacement of, but rather as a consolidated complement to, various society guidelines regarding perioperative anti-hyperglycemic agent management.

• Publication year

  2024

• Venue

  Journal of Clinical Medicine

• Publication date

  2024-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3390/jcm13206259PMID 39458209PMCID 11509032
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of perioperative discontinuation of SGLT2 inhibitors.

  2024cited by this paper
• Mechanistic Modeling of Empagliflozin: Predicting Pharmacokinetics, Urinary Glucose Excretion, and Investigating Compensatory Role of SGLT1 in Renal Glucose Reabsorption

  2024cited by this paper
• Risks of peri‐ and postoperative complications with glucagon‐like peptide‐1 receptor agonists

  2024cited by this paper
• Incidence of sodium–glucose cotransporter-2 inhibitor-associated perioperative ketoacidosis in surgical patients: a prospective cohort study

  2024cited by this paper
• Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis.

  2023cited by this paper
• Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study.

  2023cited by this paper
• Development and validation of a prediction model of perioperative hypoglycemia risk in patients with type 2 diabetes undergoing elective surgery

  2022cited by this paper
• Inpatient perioperative euglycemic DKA due to SGLT2 inhibitors - lessons from a case series and strategies to decrease incidence.

  2022cited by this paper
• Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects.

  2022cited by this paper
• Association of Glucagon-like Peptide 1 Analogs and Agonists Administered for Obesity with Weight Loss and Adverse Events: A Systematic Review and Network Meta-analysis

  2021cited by this paper
• "The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics".

  2021cited by this paper
• Euglycemic Ketoacidosis as a Complication of SGLT2 Inhibitor Therapy.

  2021cited by this paper
• SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms

  2021cited by this paper
• The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.

  2021cited by this paper
• 15. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2021.

  2021cited by this paper
• Incretin‐Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes

  2021cited by this paper
• Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

  2020cited by this paper
• Perioperative glucose management: Current status and future directions.

  2020cited by this paper
• Perioperative Management of Oral Glucose-lowering Drugs in the Patient with Type 2 Diabetes.

  2020influential reference
• Sitagliptin for the prevention and treatment of perioperative hyperglycaemia in patients with type 2 diabetes undergoing cardiac surgery: A randomized controlled trial

  2020cited by this paper
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

  2019cited by this paper
• Recent advances in diabetes treatments and their perioperative implications

  2019cited by this paper
• Perioperative Glucose Control in Patients With Diabetes Undergoing Elective Surgery

  2019cited by this paper
• Glycaemic efficacy and safety of linagliptin compared to a basal‐bolus insulin regimen in patients with type 2 diabetes undergoing non‐cardiac surgery: A multicentre randomized clinical trial

  2019cited by this paper
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

  2019cited by this paper
• Metformin

  2019cited by this paper
• Updates in Glycemic Management in the Hospital

  2019cited by this paper
• Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.

  2019cited by this paper
• Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist

  2018cited by this paper
• Critical appraisal and systematic review of guidelines for perioperative diabetes management: 2011–2017

  2018cited by this paper
• Practical management of diabetes patients before, during and after surgery: A joint French diabetology and anaesthesiology position statement.

  2018cited by this paper
• Cardioprotection by Metformin: Beneficial Effects Beyond Glucose Reduction

  2018cited by this paper
• Peri‐operative continuation of metformin does not improve glycaemic control in patients with type 2 diabetes: A randomized controlled trial

  2018cited by this paper
• The mechanisms of action of metformin

  2017cited by this paper
• Evaluation of the Effect of Metformin and Insulin in Hyperglycemia Treatment after Coronary Artery Bypass Surgery in Nondiabetic Patients

  2017cited by this paper
• Inhibition of Renal Sodium–Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose

  2017cited by this paper
• Metformin: historical overview

  2017cited by this paper
• Perioperative Hyperglycemia Management: An Update

  2017cited by this paper
• Pharmacologic Profile of Naloxegol, a Peripherally Acting µ-Opioid Receptor Antagonist, for the Treatment of Opioid-Induced Constipation

  2017cited by this paper
• Safety and efficacy of saxagliptin for glycemic control in non-critically ill hospitalized patients

  2017cited by this paper
• Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.

  2017cited by this paper
• Effect of dipeptidyl peptidase-4 inhibitor in patients undergoing bypass surgery

  2016cited by this paper
• Metformin-associated lactic acidosis: Current perspectives on causes and risk.

  2016cited by this paper
• Sulfonylureas and their use in clinical practice

  2015cited by this paper
• The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

  2015cited by this paper
• Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

  2015cited by this paper
• Peri‐operative management of the surgical patient with diabetes 2015

  2015cited by this paper
• Metabolic response to the stress of critical illness.

  2014cited by this paper
• Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations

  2014cited by this paper
• Effects of GLP-1 on appetite and weight

  2014cited by this paper
• The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus

  2013cited by this paper
• Estimating the effect of sulfonylurea on HbA1c in diabetes: a systematic review and meta-analysis

  2013influential reference
• Randomized Study Comparing a Basal-Bolus With a Basal Plus Correction Insulin Regimen for the Hospital Management of Medical and Surgical Patients With Type 2 Diabetes

  2013cited by this paper
• Longer term safety of dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta‐analysis

  2012cited by this paper
• NHS Diabetes guideline for the perioperative management of the adult patient with diabetes *

  2012cited by this paper
• Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications.

  2012cited by this paper
• Biology of human sodium glucose transporters.

  2011cited by this paper
• Metformin as an adjunct to insulin for glycemic control in patients with type 2 diabetes after CABG surgery: a randomized double blind clinical trial.

  2011cited by this paper
• Dipeptidylpeptidase-4 Inhibitors (Gliptins)

  2010cited by this paper
• Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation.

  2010cited by this paper
• Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

  2010cited by this paper
• Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus.

  2010cited by this paper
• Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

  2010cited by this paper
• Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes

  2009cited by this paper
• A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin‐treated patients

  2009cited by this paper
• American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control.

  2009cited by this paper
• Management of diabetes and hyperglycemia in the hospital: a practical guide to subcutaneous insulin use in the non-critically ill, adult patient.

  2008cited by this paper
• Peroxisome Proliferator-Activated Receptor γ and Adipose Tissue—Understanding Obesity-Related Changes in Regulation of Lipid and Glucose Metabolism

  2007cited by this paper
• Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism.

  2007cited by this paper
• Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

  2006cited by this paper
• Perioperative glucose control in the diabetic or nondiabetic patient.

  2006cited by this paper
• Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.

  2006cited by this paper
• Evaluation of intramuscular ceruletide for shortening small bowel transit time

  2005cited by this paper
• Management of diabetes and hyperglycemia in hospitals.

  2004cited by this paper
• The mode of action of thiazolidinediones

  2002cited by this paper
• Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.

  1999cited by this paper
• A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44)

  1999cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Acarbose-induced acute severe hepatotoxicity.

  1997cited by this paper
• Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion.

  1995cited by this paper
• Perioperative Management of Diabetic Subjects: Subcutaneous Versus Intravenous Insulin Administration During Glucose-Potassium Infusion

  1988cited by this paper
• Postoperative Management of Diabetes Mellitus: Steady-State Glucose Control With Bedside Algorithm for Insulin Adjustment

  1987cited by this paper
• Small intestine transit time in the normal small bowel study.

  1968cited by this paper
• American

  1898cited by this paper

• Agent- and Dose-Specific Intestinal Obstruction Safety of GLP-1 Receptor Agonists and SGLT2 Inhibitors: A Network Meta-Analysis of Randomized Trials

  2026cites this paper
• Weight Reduction with GLP-1 Agonists and Paths for Discontinuation While Maintaining Weight Loss

  2025cites this paper
• Perioperative Management of Diabetic Medications in Patients Undergoing Elective Total Joint Arthroplasty: A Review of Current Guidelines and Recommendations.

  2025cites this paper
• Non-insulin diabetes medicines: an emerging role in pain management? Comment on Br J Anaesth 2025; 135: 898-911.

  2025cites this paper
• Semaglutide/Opioid-analgesics

  2024cites this paper